Effect of Combination Therapy with Anti-PD-1 Antibody and dasatinib on Liver Metastases in an Experimental Mouse Model

In order to investigate whether dasatinib, a stromal inhibitor, could increase the sensitivity to immunotherapy for metastatic colorectal cancer, we generated a mouse model of liver metastasis. We performed a comprehensive gene expression profiling analysis by extracting toral RNA from liver metastases of mice treated with immunotherapy alone or with immunotherapy and dasatinib. Comparative gene expression profiling analysis of RNA-seq data for liver metastases of mice that received only immunotherapy with anti-PD-1 antibody and those that received immunotherapy and dasatinib